Company intelligence
Abzena
Abzena is the leading integrated bioconjugate & complex biologics CDMO+CRO, focused on rapidly moving medicines forward.
About Abzena
Abzena is the leading end-to-end bioconjugate, ADC, and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule and move medicines forward faster. The company has research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK.
Verified activity
Signals from Abzena
6 published signals
Research & Knowledge
Abzena published an article outlining where ADCs and AOCs diverge, including OAR tolerance, charge density, maleimide-thiol linkages, and cleavable vs. non-cleavable linkers.
Reported by Abzena
Products & Services
Abzena runs head-to-head comparative studies across conjugation chemistry, release mechanism, and OAR early in development.
Reported by Abzena
Presence & Recognition
Abzena is the major sponsor of the PBSS Workshop on IND Filing and Nonclinical Considerations for Emerging Modalities on Sept. 9 in Cambridge, MA.
Reported by Abzena
Presence & Recognition
Abzena's CFO Thomas Castellano shared how drug developers are now weighing regulatory certainty, supply reliability, and reputational risk alongside price in Pharma's Almanac industry roundtable.
Reported by Abzena
Presence & Recognition
Abzena CEO Geoffrey Glass and CSO Campbell Bunce discuss AOC manufacturing considerations and market pressures in a latest PharmaSource podcast.
Reported by Abzena
Presence & Recognition
Abzena was recognized as a Top ADC & AOC CDMO Solution Provider of 2026
Reported by Edward E. Rivera